Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 3Phase 1/2 2

Status

Completed 3Unknown 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × HMPL-013 × Clear all
NCT03251378 2024-09-25

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Hutchmed

Phase 1 Completed
129 enrolled 32 charts
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Triple Negative Breast Neoplasms

NCT05368805 2022-10-06

Fruquintinib DDI Study With P-gp and BCRP Substrates

Hutchmed

Phase 1 Completed
32 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01645215 2020-02-17

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1 Completed
40 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡